Titre :
  • An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer.
Auteur : Piccart-Gebhart, Martine ; Bruning, Peter ; Gamucci, T ; Klijn, J G ; Roy, J A ; Awada, Ahmad ; Kusenda, Zlatko ; Van Vreckem, A ; Paridaens, Robert
Informations sur la publication : Seminars in oncology, 23, 5 Suppl 11, (page 11-15)
Statut de publication : Publié, 1996-10
Sujet CREF : Sciences bio-médicales et agricoles
Mots-clés MeSH : Adenocarcinoma -- drug therapy
Adult
Aged
Antibiotics, Antineoplastic -- administration & dosage
Antibiotics, Antineoplastic -- adverse effects
Antibiotics, Antineoplastic -- therapeutic use
Antineoplastic Agents, Phytogenic -- administration & dosage
Antineoplastic Agents, Phytogenic -- adverse effects
Antineoplastic Agents, Phytogenic -- therapeutic use
Breast Neoplasms -- drug therapy
Cross-Over Studies
Disease Progression
Doxorubicin -- administration & dosage
Doxorubicin -- adverse effects
Doxorubicin -- therapeutic use
Europe
Female
Heart Failure -- chemically induced
Humans
Infusions, Intravenous
Injections, Intravenous
Middle Aged
Neutropenia -- chemically induced
Paclitaxel -- administration & dosage
Paclitaxel -- adverse effects
Paclitaxel -- therapeutic use
Prospective Studies
Remission Induction
Note : Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Langue :
  • Anglais
Identificateurs : urn:issn:0093-7754 
info:pmid/8893893